BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35093506)

  • 1. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
    BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
    Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G
    Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
    de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
    J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
    Ebraheem M; Kumar SK; Dispenzieri A; Jevremovic D; Buadi FK; Dingli D; Cook J; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Binder M; Lin Y; Go RS; Siddiqui MA; Kyle RA; Rajkumar SV; Gonsalves WI; Gertz MA
    Transplant Cell Ther; 2022 Nov; 28(11):760.e1-760.e5. PubMed ID: 35940527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
    Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
    Bhutani M; Foureau D; Zhang Q; Robinson M; Wynn AS; Steuerwald NM; Druhan LJ; Guo F; Rigby K; Turner M; Slaughter D; Friend R; Atrash S; Symanowski JT; Avalos BR; Copelan EA; Voorhees PM; Usmani SZ
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):459-465. PubMed ID: 30481597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
    Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
    Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
    Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
    Belotti A; Ribolla R; Cancelli V; Villanacci A; Angelini V; Chiarini M; Giustini V; Facchetti GV; Roccaro AM; Ferrari S; Peli A; Bottelli C; Cattaneo C; Crippa C; Micilotta M; Frittoli B; Grazioli L; Rossi G; Tucci A
    Cancer Med; 2021 Sep; 10(17):5859-5865. PubMed ID: 34263564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
    Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
    Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
    Paiva B; Vidriales MB; Cerveró J; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de Las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF;
    Blood; 2008 Nov; 112(10):4017-23. PubMed ID: 18669875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.
    Nahi H; Afram G; Uttervall K; Lockmer S; Tätting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
    Cancer Med; 2023 Nov; 12(22):20736-20744. PubMed ID: 37921243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
    Coffey DG; Osman K; Aleman A; Bekri S; Kats S; Dhadwal A; Catamero D; Kim-Schulze S; Gnjatic S; Chari A; Parekh S; Jagannath S; Cho HJ
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation.
    Porrata LF; Gastineau DA; Padley D; Bundy K; Markovic SN
    Leuk Lymphoma; 2003 Jun; 44(6):997-1000. PubMed ID: 12854901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
    Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
    Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
    Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
    Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS
    Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.